# Gregory B. Lesinski

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gregory-b-lesinski/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,542 |
| Field | Pancreatic and Hepatic Oncology Research |
| h-index | 52 |
| i10-index | 125 |
| Last Known Institution | Emory University |
| OpenAlex ID | https://openalex.org/A5032094154 |
| ORCID iD | 0000-0002-8787-7678 |
| Works | 522 |

## Researcher papers

- [IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer](https://scholariq.org/papers/il-6-and-pd-l1-antibody-blockade-combination-therapy-reduces-tumour-progression/)
- [Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms](https://scholariq.org/papers/immune-checkpoint-inhibitors-for-the-treatment-of-msi-h-mmr-d-colorectal-cancer/)
- [Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner](https://scholariq.org/papers/pancreatic-cancer-associated-stellate-cells-promote-differentiation-of-myeloid/)
- [β-Blockers and Survival among Danish Patients with Malignant Melanoma: A Population-Based Cohort Study](https://scholariq.org/papers/blockers-and-survival-among-danish-patients-with-malignant-melanoma-a-population/)
- [Enhanced bioavailability of lycopene when consumed as <i>cis</i>‐isomers from <i>tangerine</i> compared to red tomato juice, a randomized, cross‐over clinical trial](https://scholariq.org/papers/enhanced-bioavailability-of-lycopene-when-consumed-as-i-cis-i-isomers-from-i/)
- [Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice](https://scholariq.org/papers/myeloid-derived-suppressor-cell-inhibition-of-the-ifn-response-in-tumor-bearing/)
- [Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment](https://scholariq.org/papers/lipocalin-2-promotes-pancreatic-ductal-adenocarcinoma-by-regulating-inflammation/)
- [Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma](https://scholariq.org/papers/randomized-phase-2-trial-of-the-oncolytic-virus-pelareorep-reolysin-in-upfront/)
- [The Potential of CAR T Cell Therapy in Pancreatic Cancer](https://scholariq.org/papers/the-potential-of-car-t-cell-therapy-in-pancreatic-cancer/)
- [A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells](https://scholariq.org/papers/a-novel-small-molecule-inhibits-stat3-phosphorylation-and-dna-binding-activity/)
- [Consumption of Soy Isoflavone Enriched Bread in Men with Prostate Cancer Is Associated with Reduced Proinflammatory Cytokines and Immunosuppressive Cells](https://scholariq.org/papers/consumption-of-soy-isoflavone-enriched-bread-in-men-with-prostate-cancer-is/)
- [Isoflavone Pharmacokinetics and Metabolism after Consumption of a Standardized Soy and Soy–Almond Bread in Men with Asymptomatic Prostate Cancer](https://scholariq.org/papers/isoflavone-pharmacokinetics-and-metabolism-after-consumption-of-a-standardized/)

## Researcher topics

- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Research and Treatments](https://scholariq.org/topics/cancer-research-and-treatments/)

## Researcher university

- [Emory University](https://scholariq.org/institutions/emory-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.